Capricor Therapeutics Inc. reported new Phase 3 HOPE-3 trial data showing its Duchenne Muscular Dystrophy (DMD) therapy Deramiocel improved key heart function measures and reduced cardiac fibrosis. The treatment regulatory application is under review by the US Food and Drug Administration, with a decision expected on August 22, 2026.
Sponsored Advertisement
No comments yet. Be the first!